About me

 

Welcome, let me introduce myself, I’m Laura Llacuna, Biologist, PhD in Biomedicine, Health Coach and Psiconeuroimmunologist. I’m passionate about life, discovering the world, healthy foods, nature and dance.

I work on Integrative Medicine, offering a holistic vision about human health and helping patients that come to my consult disoriented and looking for alternatives to conventional medicine.

I help them to establish the changes that they need to achieve their objectives and get a better health and happiness.

My goal is to connect with people, give them opportunities to new solutions and healthy lifestyle. Is basic to be conscious about the needs of every single person because everyone is unique and different and that is why I offer a comfortable environment where the bioindividuality and the passion of everyone is important in order to choose the correct foods and decide the treatments to follow.

Trust your intuition and don’t regret at what makes you feel alive!

Leer más

Here you can check with more detail my Curriculum Vitae:

Colegiate Biologist: col. 22086-C

My studies:

– Degree on Biology (UB, 2003)
– Master in Biotechnology (UB, 2005)
– PhD Doctor in Biomedicine with maximum qualification and extraordinary prize (UB, 2009)
– Master in Nutrition and Public Health (UOC, 2011)
– Health Coach Certificate (Institute of Integrative Nutrition, Nueva York 2016)
– Master in PsichoNeuroImmunoEndocrinology (UB, 2017)

My trajectory:

– Health Coach and Health Therapist since 2016.
– 2013-2015. Postdoctoral fellow at Mount Sinai School of Medicine – Oncological Sciences (Nueva York, USA)
– 2009-2012. Postdoctoral fellow at IMIM-Hosptial del Mar/parc de recerca biomèdica (Barcelona)
– 2010-2011 – Postdoctoral stage at Biocenter d’Innsbruck Medical University (Austria)
– 2002-2003 – Assistant Student at Hospital St Louis de la Universidad de París (Francia)
– 2000 – Student and Research collaboration with Dra. Lynn Margullis. Departamento de Microbiología de la
Universidad de Massachussets (Amherst, USA).

 

 

Scientific Publications

-Liscio P, Carotti A, Asciutti S, Karlberg T, Bellocchi D, Llacuna L, Macchiarulo A, Aaronson SA, Schüler H, Pellicciari R, Camaioni E. Design, Synthesis, Crystallographic Studies, and Preliminary Biological Appraisal of New Substituted Triazolo[4,3-b]pyridazin-8-amine Derivatives as Tankyrase Inhibitors. J Med Chem. 2014 Mar 27;57(6):2807-12.

-Farrés J, Llacuna L, Martin-Caballero J, Martínez C, Lozano JJ, Ampurdanés C, López-Contreras AJ, Florensa L, Navarro J,Ottina E, Dantzer F, Schreiber V, Villunger A, Fernández-Capetillo O, Yélamos J. PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Cell Death Differ. 2015 Jul;22(7):1144-57.

-Florian J. Bock , Gerhard Krumschnabel , Claudia Manzl , Lukas Peintner, Natascha Hermann-Kleiter, Laura Llacuna, Jose Yelamos and Andreas Villunger. Loss of PIDD limits NF-κB activation and cytokine production but not cell survival or transformation after DNA damage. Cell Death Differ. 2013 Apr;20(4):546-57. 

Farrés J, Martín-Caballero J, Martínez C, Lozano JJ, Llacuna L, Ampurdanés C, Ruiz-Herguido C, Dantzer F, Schreiber V, Villunger A, Bigas A, Yélamos J. Parp-2 is required to maintain hematopoiesis following sublethal γ-irradiation in miceBlood. 2013 Jul 4;122(1):44-54.

–Llacuna L, Mach N. Papel de los antioxidants en la prevención del cáncer. Rev Esp Nutr Hum Diet. 2012; 16 (1): 16-24.

Yelamos J, Farrés J, Llacuna L, Ampurdanés C, Martín-Caballero J. PARP-1 and PARP-2: New players in tumor development. Am J Cancer Res 2011; 1(3): 328-346.

Angulo S, Morales A, Danese S, Llacuna L, Masamunt MC, Pultz N, Cifone MG, De Simone C, Delgado S, Vila J, Panés J, Donskey C, Fernández-Checa JC, Fiocchi C, Sans M. Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinasePLoS One. 2011 Mar 9;6(3):e16953.

–Llacuna L, Fernández A, Von Monfort C, Matías N, Martínez L, Caballero F, Rimola A, Elena M, Morales A, Fernández-Checa JC, Carmen García-Ruiz C. Targeting cholesterol at different levels in the mevalonate pathway protects fatty liver against ischemia-reperfusion injury. J Hepatol. 2011 May;54(5):1002-10.

–Llacuna L, Bárcena C, Bellido-Martín L, Fernández L, Stefanovic M, Marí M, García-Ruiz C, Fernández-Checa JC, García de Frutos P, Morales A. Growth arrest-specific protein 6 is hepatoprotective against murine ischemia/reperfusion injury. Hepatology. 2010 Oct;52(4):1371-9.

Lluis JM, Llacuna L, von Montfort C, Bárcena C, Enrich C, Morales A, Fernandez-Checa JC. GD3 synthase overexpression sensitizes hepatocarcinoma cells to hypoxia and reduces tumor growth by suppressing the cSrc/NF-kappaB survival pathway. PLoS One. 2009 Nov 26;4(11):e8059.

Fernández A, Llacuna L, Fernández-Checa JC, Anna Colell. Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity. Journal of Neuroscience, 2009 May 20;29(20):6394-405.

–Llacuna L, Marí M, Lluis JM, García-Ruiz C, Fernández-Checa JC, Morales A. Reactive oxygen species mediate liver injury through parenchymal Nf-κB inactivation in prolonged ischemia/reperfusion. American Journal Pathology, 2009 May;174(5):1776-85.

Montero J, Morales A, Llacuna L, Lluis JM, Terrones O, Basañez G, Antonsson B, Prieto J, Garcia-Ruiz C, Colell A, Fernández-Checa JC. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 2008 Jul 1;68(13):5246-56.

Morales A, Paris R, Villanueva A, Llacuna L, Garcia-Ruiz C, Fernández-Checa JC. Pharmacological inhibition of small interfering RNA targetic acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo. Oncogene. 2007 Feb 8;26(6):905-16.

–Llacuna L, Mari M, Garcia-Ruiz C, Fernández-Checa JC, Morales A. Critical role of acidic sphingomyelinase in murine hepatic ischemia-reperfusion injury. Hepatology. 2006 Sep; 44(3): 561-72.